NCT07106671View on ClinicalTrials.gov

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
CRS - Cytokine Release SyndromeMyeloma
Interventions
DRUG

Siltuximab

Siltuximab 11mg/kg

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT07106671 - A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma | Biotech Hunter | Biotech Hunter